Antioxidant Compound Library

Cat.No.L6500

A unique collection of 814 compounds used for exploring the relationship between anti-oxidation and some diseases such as aging,cancer,alzheimer's disease,parkinson's disease,diabetes,etc.

Customise Your Library:

Specific Compounds
Quantities
96 or 384 well Plate Map
Dry/solid or DMSO solution

Cited by 321 Publications

Antioxidant Compound Library Contents

Description & Advantages

•A unique collection of 814 anti-oxidation related compounds for high throughput screening (HTS) and high content screening (HCS)

•Used for exploring the relationship between anti-oxidation and some diseases such as aging,cancer,alzheimer's disease,Parkinson's disease,diabetes,etc.

•Some compounds have been approved by the FDA

•Structurally diverse,medicinally active,and cell permeable

•Rich documentation with structure and bioactivity information

•NMR and HPLC validated to ensure high purity

Product Details

Formulation	765 compounds pre-dissolved in 10mM DMSO, 33 compounds pre-dissolved in 10mM water and 16 compounds pre-dissolved in 2mM DMSO
Container	96 Deep Well Plate Sealed With Aluminium Foil
Stability	12 months	-20°C	in DMSO
Stability	24 months	-80°C	in DMSO
Shipping	Blue ice or dry ice

Case Studies using Selleck Compound Libraries

Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF

Nature.2019;574(7777):268-272
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF

Nat Commun. 2019 16;10(1):2197
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF

Cell Res. 2019;29(9):739-753
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF

Mov Disord. 2019;34(3):323-334
Application of Epigenetics Compound Library in acute lymphoblastic leukaemia (This article was published in Blood (IF

Blood. 2019 17;134(16):1323-1336
Application of Inhibitor Library in tumour immunology (This article was published in Cancer Immunol Res (IF

Cancer Immunol Res.2017;5(9):790-803